Background Health-Related Quality of Life (HRQoL) in patients with autoimmune systemic diseases has a multifactorial origin. In particular, data from the literature show that Systemic Lupus Erythematosus (SLE) correlation between HRQoL and disease manifestations is quite controversial. Objectives to evaluate impact different activity patterns on patients’ perception monocentric cohort SLE. Meth...

Background: Systemic lupus erythematosus (SLE) is a chronic disease characterized by periodic flares associated with poor outcomes and subsequent organ damage (1-2). Flare prevention important for optimal patient management development of effective therapies. Objectives: To identify patient-level factors among patients moderate/severe SLE. Methods: We conducted post-hoc analysis 260 active, aut...

Background: The EULAR recommendations for the management of systemic lupus erythematosus (SLE) suggest a hydroxychloroquine (HCQ) dose ≤5.0 mg/kg/day instead 6.5 to reduce risk HCQ-induced retinopathy (1). This change in HCQ may potentially lead undertreatment with blood levels below presumed therapeutic range. Objectives: aim this study was compare flare rates and between two different oral do...

Background: Lupus Low Disease Activity State (LLDAS) is a target for management of patients with SLE, that should be maintained in the long-term by preventing flares. Stratification flare risk would useful to optimize management. Objectives: To identify predictors SLE attaining LLDAS. Methods: Patients fulfilling classification criteria [ACR (1997) and/or SLICC EULAR/ACR], followed at an academ...

Background: In patients with SLE, activation of the CD40–CD40L pathway results in stimulation and proliferation B cells other inflammatory cell types. The subsequent generation autoantibodies their deposition kidney, as well myeloid resident kidney cells, result local inflammation eventually, injury. Thus, CD40 is an appealing therapeutic target lupus nephritis (LN). BI 655064 a humanised anti-...

Table 1 shows the terms and symbols used for standardized representation of our recommendations. Cutaneous lupus erythematosus (CLE) is a rare, inflammatory autoimmune skin disease with heterogeneous clinical appearance. Currently, there no treatment specifically approved this disease. Topical systemic medications are off label. The goal guideline to provide consensus-based recommendations on d...